D-Chiro Inositol (DCI) is one of the two biologically active forms of inositol your body uses to relay insulin signals inside cells. It also happens to be a transcriptional inhibitor of aromatase, the enzyme that converts testosterone into oestrogen. That second property is why it sits in a different conversation from myo-inositol, the form most people mean when they say “
Inositol”.
In practice, DCI on its own is a niche tool. Most people supplementing for PCOS, fertility, anxiety, or general metabolic health are better off with myo-inositol or the 40:1 myo-to-DCI blend. The places where DCI alone is actually interesting are men with low testosterone driven by high aromatase (overweight, older, on cycle, or coming off cycle), and specific metabolic protocols where insulin sensitisation is the main goal and reproductive concerns don't apply. For women of reproductive age, DCI alone at the doses sold in most supplements can do the opposite of what you want, and this is worth understanding before buying it.
Deep-dive
Inositol exists as nine stereoisomers but only two matter in humans: myo-inositol (MI), which makes up over 99% of the body's inositol pool, and D-chiro-inositol (DCI), produced from MI by an insulin-dependent epimerase. Plasma normally sits at roughly a 40:1 MI:DCI ratio, and inside the ovary the ratio is closer to 100:1. DCI's biological job is to act as a second messenger for insulin via DCI-containing inositol phosphoglycans, distinct from the classical PI3K/Akt pathway. When you take DCI orally, you're adding substrate to that arm of insulin signalling, which is why it can lower fasting insulin and improve glucose handling.
Aromatase inhibition is the other half of the story. DCI down-regulates the transcription of CYP19A1, the gene encoding aromatase. Aromatase converts androgens (testosterone, androstenedione) into oestrogens (oestradiol, oestrone). In the ovary, aromatase activity is high by design, since oestrogen synthesis is part of normal follicle development. Suppress it too aggressively and follicles stop maturing properly. In male tissue and in adipose tissue, baseline aromatase activity is much lower, and inhibiting it modestly tilts the androgen/oestrogen ratio toward androgens. This is the mechanism behind every interesting effect DCI has, both the helpful ones and the harmful ones.
Men with low testosterone. This is the clearest case for DCI alone. A 2021 pilot study in male volunteers given 1 g/day DCI for 30 days saw serum testosterone rise by about 23%, DHEA by 14%, and epiandrosterone by 39%, while oestrone dropped 85% and oestradiol dropped 14%. FSH, LH, and inhibin B didn't change, which suggests the effect is local at the aromatase level rather than a feedback-driven HPG axis change. A follow-up pilot in older hypogonadal men with low-normal testosterone replicated the testosterone and androstenedione increase with no adverse events. These are small open-label pilots, not large blinded RCTs, so the effect size is preliminary, but the mechanism is biologically coherent and the safety profile in men has been clean across the trials. Adipose tissue is one of the main extra-gonadal sites of aromatase, so overweight men with high body fat tend to have the highest aromatase activity and the most room to benefit. If you're a lean young man with already-good testosterone, the ceiling is much lower.
PCOS and metabolic effects in women. The original DCI work in women is the 1999 Nestler NEJM trial, which gave 1200 mg/day DCI to obese women with PCOS for 6 to 8 weeks. The treated group had improved insulin sensitivity, lower free testosterone, lower blood pressure, lower triglycerides, and ovulation in 86% versus 27% on placebo. A follow-up in lean PCOS women used 600 mg/day and saw similar results: lower insulin, lower androgens, more ovulation. On paper this looks great. The catch came later.
The DCI overdose problem in women. Higher doses and longer courses of DCI alone do not keep working. They start working against you. A 2023 retrospective and prospective study of 1200 mg/day DCI for 6 months in insulin-resistant women and in healthy women found that DCI lowered BMI, glucose, insulin, HOMA-IR, LH, total testosterone, and DHEAS over time, but it also raised serum oestradiol and produced menstrual irregularities. Mouse models given chronic high-dose DCI develop a PCOS-like phenotype with elevated androgens, ovarian cysts, and impaired oocyte quality. The interpretation is that prolonged DCI suppresses ovarian aromatase enough to disrupt the local hormonal environment follicles need to mature. The current consensus in the inositol literature is that DCI alone is not appropriate as a long-term PCOS treatment for reproductive-age women, and that the 40:1 MI:DCI ratio (or myo-inositol alone) is the correct framing for that population. This isn't an inositol problem, it's a stereoisomer problem.
Where DCI alone may still make sense for women. Two narrow cases. First, a small case series showed 1200 mg/day DCI induced ovulation in non-PCOS, non-insulin-resistant women with anovulatory cycles likely through its mild aromatase modulation, which is interesting but very preliminary. Second, postmenopausal women, where ovarian aromatase function isn't the relevant variable and adipose-tissue aromatase is the main concern. In that group, the rationale is closer to the male rationale: limit conversion of remaining androgens to oestrogen, which can be useful for body composition and metabolic targets. Evidence here is mostly mechanistic and small-trial.
Limits of the evidence. Most of the DCI-specific human data is from small open-label studies, often run by groups with commercial interests in inositol products. Sample sizes are usually 10 to 40, follow-up is short, and the largest meta-analyses on inositol pool MI and DCI studies together. The aromatase mechanism is well-established at the molecular level. The clinical effect size in men, while consistent in direction, hasn't been validated in a large blinded trial.
Dosage:
- Men aiming to raise testosterone and lower oestrogen: 1 g/day, taken once daily, ideally with a meal. The 30-day male pilot used this dose. Reasonable to run 8 to 12 weeks then reassess with bloodwork. Higher doses haven't been studied in men and there's no clear evidence more is better
- Women of reproductive age: generally avoid DCI alone. Use myo-inositol or 40:1 MI:DCI instead, see the Inositol page. The only reasonable use cases are short courses (6 to 8 weeks) at 600 to 1200 mg/day for documented PCOS with insulin resistance under medical supervision, and even then, the 40:1 blend is usually the better choice for the same indication
- Postmenopausal women: 500 mg to 1 g/day is reasonable for metabolic and body composition goals if that's the use case. Run for 8 to 12 weeks and reassess
- Timing and form: standard powder or capsules. No clear advantage to one form. With food is fine and probably preferable for GI tolerance at the higher end. Splitting into 500 mg twice daily is also reasonable
- Don't stack DCI with high-DCI ratio inositol products (1:1, 5:1, 20:1). You'll just be taking the same compound twice. The whole point of those blends is that they already contain DCI
- Cycling. Most of the human safety data runs out at 3 to 6 months. If using long-term, take 2 to 4 weeks off every 3 months, particularly relevant for women
Here's what you can expect:
For men using it to raise testosterone, expect bloodwork to move before you notice much subjectively. Total testosterone and oestradiol should shift within 4 weeks, with most of the effect visible by 8 to 12 weeks. The subjective changes (libido, recovery, training response) lag the numbers and are easier to attribute confidently if you have a clean baseline panel. If your starting testosterone is already in the upper half of the range, expect modest gains. If you're hypogonadal or low-normal with high body fat, the room to move is larger.
For PCOS or metabolic use in women, the timeline mirrors inositol generally: insulin and androgen markers shift in 4 to 8 weeks, cycle effects need 3 months to read clearly. The reason to use the 40:1 blend instead of DCI alone is that you get the same metabolic benefit without the aromatase suppression risk on ovarian function.
For cycle or PCT support, the read-out is your oestradiol response on bloodwork rather than anything you'll feel. Don't dose it based on subjective "feel".
If nothing shifts on bloodwork at 12 weeks of a real dose, DCI isn't your compound. The aromatase effect is real but modest. It won't overcome a high aromatase load from heavy adiposity or a serious androgen deficit on its own. It's a lever, not a fix.
Side effects & risks:
- GI side effects are the main short-term issue, mainly nausea or loose stools. Dose-dependent and uncommon at 1 g/day. Splitting the dose or taking with food handles most cases
- Disrupted cycles and worsened ovarian function in reproductive-age women is the headline risk and the reason most women shouldn't use DCI alone. Long-term high-dose DCI suppresses ovarian aromatase enough to disrupt follicular development, raise local androgens, and produce menstrual irregularities. This is the dose- and duration-dependent problem the 40:1 blend exists to avoid
- Crashed oestradiol is theoretically possible with high doses or stacking with a pharmaceutical aromatase inhibitor. Symptoms are joint pain, low libido, dry skin, low mood. Unlikely at 1 g/day DCI alone in someone not on an AI, but worth knowing if you're stacking
- Hypoglycaemia if combined with insulin, sulfonylureas, or other glucose-lowering agents. DCI lowers fasting insulin and can drop blood sugar mildly on its own. Monitor more frequently in the first month if you're stacking
- Pregnancy and breastfeeding. Skip it. Myo-inositol at 4 g/day has strong safety data in pregnancy. DCI alone does not, and the aromatase suppression mechanism is a theoretical concern in early gestation
- Bipolar disorder caution. Inositol generally has occasionally triggered mania or hypomania in susceptible individuals. Smaller risk at DCI doses (1 g) than at the 12 to 18 g/day used for psychiatric indications, but worth flagging
- Long-term safety beyond 6 months is not well characterised. Most human trials top out at 6 months. Long-running supplementation at 1 g/day in men hasn't been formally studied beyond that
- Drug interactions are generally clean outside the glucose-lowering category and stacking with pharmaceutical aromatase inhibitors
Blood markers
Total testosterone, free testosterone, SHBG, oestradiol (E2), oestrone (E1) where available, baseline before starting and at 8 to 12 weeks. This is the panel that tells you whether DCI is actually moving the needle on aromatase activity. For men, the goal is testosterone up, oestradiol stable or slightly down, with E2 staying within a healthy range (don't aim to crush it)
DHEA-S, baseline and at 12 weeks if you're a man tracking the full androgen panel. The male pilot showed DHEA-S moves alongside testosterone
Fasting insulin, glucose, HOMA-IR, baseline and at 12 weeks for anyone using DCI for metabolic reasons or running it during a cycle. This is where the insulin-second-messenger effect shows up
Cycle tracking (basal body temperature, LH strips, or progesterone in the luteal phase) for any woman using DCI, especially short courses for PCOS. If cycles lengthen, ovulation disappears, or LH stays suppressed past week 4 to 6, stop and switch to myo-inositol or 40:1
HbA1c, baseline and at 12 weeks if using long-term for metabolic goals
Sold as a dietary supplement in most countries.
Made with Bullet